Re: TKMR
NEW YORK (TheStreet) -- Tekmira Pharmaceuticals (TKMR) shares are falling sharply, down 12.5% to $25.84 on Monday, after analysts at Leerink Swann downgraded the stock to "market perform" from "outperform."
The firm also raised the company's price target to $30 from $25 despite the downgraded outlook.
TKMR